Regulus Therapeutics
RGLS
#7024
Rank
โ‚น51.09 B
Marketcap
โ‚น738.00
Share price
0.00%
Change (1 day)
458.44%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -โ‚น4.02 Billion

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -โ‚น4.18 Billion a decrease over its 2023 earnings that were of -โ‚น2.67 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -โ‚น4.02 Billion-3.99%
2024 -โ‚น4.18 Billion56.97%
2023 -โ‚น2.67 Billion6.51%
2022 -โ‚น2.5 Billion2.53%
2021 -โ‚น2.44 Billion93.59%
2020 -โ‚น1.26 Billion-15.41%
2019 -โ‚น1.49 Billion-64.46%
2018 -โ‚น4.19 Billion-33.26%
2017 -โ‚น6.28 Billion-13.98%
2016 -โ‚น7.3 Billion44.77%
2015 -โ‚น5.04 Billion-1.63%
2014 -โ‚น5.13 Billion203.6%
2013 -โ‚น1.69 Billion8.65%
2012 -โ‚น1.56 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
โ‚น823.03 B-19,287.12%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
โ‚น172.19 B-4,114.42%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น726.51 B-17,036.90%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚น1.183 T-27,699.15%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
โ‚น843.17 B-19,756.54%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-โ‚น9.87 Billion 129.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-โ‚น10.65 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
โ‚น11.78 B-374.76%๐Ÿ‡บ๐Ÿ‡ธ USA